Form 4: Mirum Pharmaceuticals Director Patrick J. Heron Reports Stock Purchases

Director Patrick J. Heron reported purchases of Mirum Pharmaceuticals (MIRM) common stock through Frazier Life Sciences X, L.P.

Summary

• On March 10, 2025, Patrick J. Heron, a director of Mirum Pharmaceuticals, reported purchasing 758 shares of common stock at a weighted average price of $42.6642.
• An additional 577 shares were purchased on the same day at a weighted average price of $43.368.
• On March 11, 2025, 963 shares were purchased at a weighted average price of $43.7748.
• These purchases were made indirectly through Frazier Life Sciences X, L.P., where Heron is a managing member but disclaims beneficial ownership except to the extent of his pecuniary interest.
• Heron also indirectly holds 3,566,912 shares through Frazier Life Sciences IX, L.P.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock purchases by a director. It doesn't inherently indicate positive or negative sentiment about the company's future.

Positives

• The director's stock purchases could be interpreted as a positive signal about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can influence investor sentiment.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive sign, potentially increasing investor confidence.

Key Dates